Enfortumab vedotin is an antibody drug conjugate used to treat advanced urothelial cancer, with skin toxicity among its most common adverse effects. To investigate this question, researchers conducted a retrospective study of patients treated with enfortumab vedotin between 2020 and 2025. Patient characteristics were reviewed manually, and cutaneous adverse events were carefully attributed to enfortumab vedotin or alternative causes using a structured likelihood scoring system. Patients who developed enfortumab vedotin induced cutaneous adverse events experienced significantly improved outcomes. Findings Suggested Prognostic PotentialEarly onset enfortumab vedotin induced cutaneous adverse events were associated with improved survival throughout the study period.